Sandbox:khurram: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
| colspan=" | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | |||
! colspan=" | |||
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | | colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
! colspan=" | ! colspan="3" rowspan="2" |Physical examination | ||
|- | |- | ||
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
Line 32: | Line 28: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ||
!aPTT | !aPTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding time | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding time | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Doppler ultrasound | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Doppler ultrasound | ||
Line 49: | Line 44: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Increase in PTT after administration of heparin | Increase in PTT after administration of heparin | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 72: | Line 66: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|Increased | |Increased | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 103: | Line 96: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 136: | Line 128: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 160: | Line 151: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 180: | Line 170: | ||
| style="background: #F5F5F5; padding: 5px;" |Increased | | style="background: #F5F5F5; padding: 5px;" |Increased | ||
|Increased | |Increased | ||
| style="background: #F5F5F5; padding: 5px;" |Increased | | style="background: #F5F5F5; padding: 5px;" |Increased | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 191: | Line 180: | ||
* Decreased fibrinogen | * Decreased fibrinogen | ||
* Decreased factor V and VIII | * Decreased factor V and VIII | ||
* Shistocytes (helmet cells) on peripheral blood smear | |||
|- | |- | ||
|Antiphospholipid antibody syndrome | |Antiphospholipid antibody syndrome | ||
| | | | ||
| | | | ||
Line 212: | Line 201: | ||
|- | |- | ||
|Heparin induced thrombocytopenia (HIT) | |Heparin induced thrombocytopenia (HIT) | ||
| | | | ||
| | | |
Revision as of 16:20, 24 August 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||
Symptoms of DVT | Symptoms of Pulmonary Embolism | Symptoms of Myocardial Infarction | Tenderness in extremities | Edema in extremities | Warmth in extremities | Platelet count | PT | aPTT | Bleeding time | Doppler ultrasound | Chest CT scan | Head CT with contrast | ||||
Antithrombin deficiency[1] | + | + | - | + | + | + | - | - | -
Increase in PTT after administration of heparin |
- |
|
| ||||
Factor V Leiden mutation[2][3] | + | + | + | + | + | + | Increased |
| ||||||||
Protein C deficiency[4] | + | + | - | + | + | + |
|
| ||||||||
Protein S deficiency[5] | + | + | - | + | + | + |
|
| ||||||||
Prothrombin gene mutation | ||||||||||||||||
Disseminated intravascular coagulation (DIC)[6][7] | + | + | +/- | + | + | + | Decreased | Increased | Increased | Increased | N/A |
| ||||
Antiphospholipid antibody syndrome | ||||||||||||||||
Heparin induced thrombocytopenia (HIT) |
References
- ↑ Patnaik MM, Moll S (November 2008). "Inherited antithrombin deficiency: a review". Haemophilia. 14 (6): 1229–39. doi:10.1111/j.1365-2516.2008.01830.x. PMID 19141163.
- ↑ Mannucci PM, Asselta R, Duga S, Guella I, Spreafico M, Lotta L, Merlini PA, Peyvandi F, Kathiresan S, Ardissino D (October 2010). "The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease". J. Thromb. Haemost. 8 (10): 2116–21. doi:10.1111/j.1538-7836.2010.03982.x. PMID 20626623.
- ↑ Campello E, Spiezia L, Simioni P (December 2016). "Diagnosis and management of factor V Leiden". Expert Rev Hematol. 9 (12): 1139–1149. doi:10.1080/17474086.2016.1249364. PMID 27797270.
- ↑ Bernard Khor & Elizabeth M. Van Cott (2010). "Laboratory tests for protein C deficiency". American journal of hematology. 85 (6): 440–442. doi:10.1002/ajh.21679. PMID 20309856. Unknown parameter
|month=
ignored (help) - ↑ Kristi J. Smock, Elizabeth A. Plumhoff, Piet Meijer, Peihong Hsu, Nicole D. Zantek, Nahla M. Heikal & Elizabeth M. Van Cott (2016). "Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories". Thrombosis and haemostasis. 116 (1): 50–57. doi:10.1160/TH15-12-0918. PMID 27075008. Unknown parameter
|month=
ignored (help) - ↑ Venugopal A (September 2014). "Disseminated intravascular coagulation". Indian J Anaesth. 58 (5): 603–8. doi:10.4103/0019-5049.144666. PMC 4260307. PMID 25535423.
- ↑ Makruasi N (November 2015). "Treatment of Disseminated Intravascular Coagulation". J Med Assoc Thai. 98 Suppl 10: S45–51. PMID 27276832.